IA can be considered to be more efficient in its cytotoxic activity and selectivity for breast cancer cells, and it can act in a similar way regardless of the cancer subtype (triple-negative, HER2, or luminal A); therefore, it is a compound that could be used against almost any subtype of breast cancer. Here, ERBB2 is linked to breast cancer.